Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Metabolic Genetics

Long-Term Monitoring and Your Child's Future

At a Glance

With early, consistent biotin treatment and regular follow-up, many children with holocarboxylase synthetase (HLCS) deficiency grow and develop well. Ongoing metabolic, developmental, hearing, and illness monitoring supports a healthy future.

The diagnosis of Holocarboxylase Synthetase (HLCS) deficiency is lifelong, but the outlook for many children is optimistic. When treatment starts early and is followed strictly, many children grow and develop steadily alongside their peers [1][2].

Long-Term Outlook and Development

For children who receive prompt biotin treatment, the clinical trajectory is often highly favorable.

  • Physical and Mental Growth: Studies of children treated since infancy show they frequently achieve near-normal height, weight, and development, and frequently meet all their major developmental milestones on time [1][3][4].
  • Stability: With daily biotin, many children achieve stable health and avoid the dangerous metabolic crises described in earlier sections [5][1]. However, outcomes depend heavily on disease severity, the child’s specific genetic profile, and whether any neurologic injury occurred before treatment began.
  • Educational Support: Children should receive ordinary developmental surveillance. Any delay, regression, seizure, hearing concern, or change in behavior should prompt clinical review by your pediatrician and metabolic team, rather than being automatically attributed to HLCS deficiency alone.

Ongoing Monitoring and Care

Even when a child is doing well, they need regular follow-up with a metabolic genetics team. The metabolic team will set the specific schedule and determine which tests are necessary based on your child’s phenotype and treatment response.

Your individualized monitoring plan may include:

  • Metabolic Lab Work: Periodic blood and urine tests to check levels of lactate, ammonia, and specific markers like 3-hydroxyisovaleric acid [6][7]. This is distinct from testing done during a crisis.
  • Growth and Nutrition: Regular checks of height and weight. Children generally do not need a special protein-restricted diet unless specifically prescribed by the metabolic team; the key is regular intake and avoiding prolonged fasting [1].
  • Neurological Checks: Monitoring for any changes in muscle tone or seizures [6].
  • Hearing and Vision: Because some children may experience hearing damage, baseline and periodic hearing screens are often recommended [8][1].
  • Dermatology: Persistent skin rashes or hair loss that do not fully resolve with biotin may require specialized skin care [9].

Thinking About the Future: Family Planning

HLCS deficiency is an autosomal recessive condition. This means that for your child to have the condition, both parents must be “carriers” of a non-working copy of the HLCS gene [5].

  • Recurrence Risk: For parents who are both carriers, there is a 25% (1 in 4) chance with each future pregnancy that the baby will also have HLCS deficiency [5].
  • Sibling Testing: Because newborn screening can occasionally miss a case [10], experts often recommend prompt targeted familial-variant testing or appropriate biochemical testing for all at-risk siblings—especially infants—even if they appear perfectly well [11].
  • Genetic Counseling: A genetic counselor can help you understand these risks and discuss options for family planning, such as preconception genetic testing, metabolic consultation, and obstetric care planning [8][12][13].

A Life of Management, Not Limitation

While your child will always need to take biotin, be extra careful during illnesses, and alert clinicians to laboratory interferences, this diagnosis does not prevent a rich and full life. By staying consistent with treatment and following the individualized illness plan, you are giving your child the foundation they need to thrive [1][3].

Common questions in this guide

What is the long-term outlook for a child with HLCS deficiency?
When biotin treatment starts early and is taken consistently, many children with HLCS deficiency grow and develop close to their peers. The outlook can vary with disease severity, the child's genetic changes, and whether neurologic injury occurred before treatment.
What follow-up tests does a child with HLCS deficiency need?
Follow-up is individualized by a metabolic genetics team and may include blood and urine tests, growth and nutrition checks, neurological examinations, and hearing and vision screening. Tests may include lactate, ammonia, and 3-hydroxyisovaleric acid, but the schedule depends on the child's condition and response to treatment.
Does a child with HLCS deficiency need a special diet?
Most children do not need a protein-restricted diet unless their metabolic team specifically prescribes one. Regular food intake and avoiding prolonged fasting are important, especially during illness, as part of the child's individualized care plan.
Should my child have regular hearing tests?
Because hearing damage can occur in some children with HLCS deficiency, a baseline hearing test and periodic hearing screens are often recommended. Your child's metabolic team can set the timing based on the child's history and ongoing health.
What is the chance that another child will have HLCS deficiency?
If both parents carry a non-working copy of the HLCS gene, each pregnancy has a 25% chance, or 1 in 4, of resulting in a child with HLCS deficiency. A genetic counselor can confirm the family's results and discuss testing and planning options.
Should healthy brothers or sisters be tested for HLCS deficiency?
At-risk siblings may need targeted testing for the family's HLCS gene change or appropriate biochemical testing, particularly when they are infants. Newborn screening can occasionally miss HLCS deficiency, so testing may be recommended even when a sibling appears well.
How is HLCS deficiency care transitioned as my child becomes an adult?
The timing and process should be planned with the metabolic genetics team as your child grows. The team can coordinate ongoing biotin treatment, illness instructions, and follow-up with an adult metabolic care provider.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific schedule for follow-up labs, growth checks, and clinical monitoring?
  2. 2.Are there specific developmental or educational milestones we should be monitoring more closely?
  3. 3.Does my child need a baseline hearing test or periodic hearing screenings?
  4. 4.If we are planning to have more children, can you help us arrange targeted carrier testing?
  5. 5.What is the recommended plan for transitioning my child's metabolic care as they grow into adulthood?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Clinical, biochemical, and genetic analysis of 28 Chinese patients with holocarboxylase synthetase deficiency.

    Ling S, Qiu W, Zhang H, et al.

    Orphanet journal of rare diseases 2023; (18(1)):48 doi:10.1186/s13023-023-02656-y.

    PMID: 36890565
  2. 2

    Dramatic Clinical Improvement With Biotin Mega-Dose Therapy in a Neonate With Holocarboxylase Synthetase Deficiency.

    Kim SW, Lee HJ, Choi N, et al.

    Molecular genetics & genomic medicine 2024; (12(8)):e70002 doi:10.1002/mgg3.70002.

    PMID: 39194177
  3. 3

    Holocarboxylase Synthetase Deficiency: Clinical, Biochemical and Molecular Findings in Five Malaysian Patients Including a Newborn Presenting as Collodion Baby.

    Ting SL, Yakob Y, Sani HA, et al.

    JIMD reports 2025; (66(2)):e70006 doi:10.1002/jmd2.70006.

    PMID: 40051682
  4. 4

    Case report of holocarboxylase synthetase deficiency (late-onset) in 2 Chinese patients.

    Xiong Z, Zhang G, Luo X, et al.

    Medicine 2020; (99(18)):e19964 doi:10.1097/MD.0000000000019964.

    PMID: 32358368
  5. 5

    Holocarboxylase synthetase deficiency: pathogenesis, clinical features, diagnosis, treatment, and research prospects.

    ZeZhao J, Ablimit A

    European journal of pediatrics 2026; (185(7)).

    PMID: 42324336
  6. 6

    Holocarboxylase synthetase deficiency pre and post newborn screening.

    Donti TR, Blackburn PR, Atwal PS

    Molecular genetics and metabolism reports 2016; (7()):40-4 doi:10.1016/j.ymgmr.2016.03.007.

    PMID: 27114915
  7. 7

    Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review.

    Wu HR, Chen KJ, Hsiao HP, Chao MC

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(11)):1481-1486.

    PMID: 32841162
  8. 8

    Clinical, biochemical, and genetic analysis of a Chinese Han pedigree with holocarboxylase synthetase deficiency: a case report.

    Zheng Z, Yuan G, Zheng M, et al.

    BMC medical genetics 2020; (21(1)):155 doi:10.1186/s12881-020-01080-4.

    PMID: 32727382
  9. 9

    Successful treatment with secukinumab of psoriasis-like dermatitis in a patient with holocarboxylase synthetase deficiency.

    Liu H, Wei R, Yang Y, et al.

    The Journal of dermatology 2023; (50(3)):401-406 doi:10.1111/1346-8138.16625.

    PMID: 36342067
  10. 10

    Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Congenital and Developmental Disorders.

    Abacan MAR, Baltazar-Braganza KR, Cabaluna ITG, et al.

    Acta medica Philippina 2026; (60(10)):28-41 doi:10.47895/amp.v60i10.10675.

    PMID: 42382931
  11. 11

    Case report: Two siblings with very late onset of holocarboxylase synthase deficiency and a mini-review.

    Gaschignard M, Domenach L, Lamireau D, et al.

    Frontiers in genetics 2024; (15()):1249480 doi:10.3389/fgene.2024.1249480.

    PMID: 39391064
  12. 12

    Paracentric Inversion of Chromosome 21 Leading to Disruption of the HLCS Gene in a Family with Holocarboxylase Synthetase Deficiency.

    Quinonez SC, Seeley AH, Lam C, et al.

    JIMD reports 2017; (34()):55-61 doi:10.1007/8904_2016_9.

    PMID: 27518780
  13. 13

    Successful pregnancy and childbirth without metabolic abnormality in a patient with holocarboxylase synthetase deficiency.

    Meguro M, Wada Y, Kisou Y, et al.

    Molecular genetics and metabolism reports 2022; (33()):100923 doi:10.1016/j.ymgmr.2022.100923.

    PMID: 36245960

This page explains long-term monitoring and family planning for a child with HLCS deficiency for educational purposes only and does not constitute medical advice. Your child's metabolic genetics team should guide monitoring, treatment, and family-planning decisions.

Get notified when new evidence is published on Holocarboxylase synthetase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.